Pipeline
Qurient has well-balanced pipeline in terms of therapeutic area and developing stage.
| Discovery | Candidate | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | |||
|---|---|---|---|---|---|---|---|---|
| Anti Cancer |
Axl/Mer/CSF1R Inhibitor (Q702) |
Immuno- oncology |
|
|||||
| Drug Resistant NSCLC |
|
|||||||
| Select CDK7 Inhibitor |
Solid tumor |
|
||||||
| Antibiotics | Cyt bc1 Inhibitor (Telacebec,Q203) |
Drug Resistant TuberCulosis |
|
|||||
| Anti Inflamation |
Topical 5LO Inhibitor (Q301) |
Atopic Dermatitis |
|
|||||
| Oral 5LO Inhibitor |
Asthma |
|
||||||
| Candidate | Pre-Clinical | Phase 1 | Phase 2 | ||
|---|---|---|---|---|---|
| Axl/Mer/ CSF1R Inhibitor (Q702) |
Immuno- oncology |
|
|
||
| Drug Resistant NSCLC |
|
|
|||
| Select CDK7 Inhibitor |
Solid tumor |
|
|||
| Cytbc1 Inhibitor (Telacebec, Q203) |
Drug Resistant TuberCulosis |
|
|
|
|
| Topical 5LO (Q301) |
Atopic Dermatitis |
|
|
|
|
| Oral 5LO Inhibitor |
Asthma |
|
|||